AzTrials
AzTrials

Advanced Solid TumorsPhase 1NCT03934359

A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

A Phase 1 study testing DN1508052-01 in people with Advanced Solid Tumors, run by Shanghai De Novo Pharmatech Co., Ltd. at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a phase I, open-label, multicenter study in adult patients with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists. DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 in 28-day cycles. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumors
What is being tested?
DN1508052-01
Type of treatment
Injection or infusion
How many people
19 participants
Where
3 sitesUnited States
Study dates
18 Sep 2019to 30 Oct 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18 years or older;
  • Patients with histologically or cytologically confirmed, unresectable advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists;
  • Patients must have at least one measurable lesion as defined by RECIST v1.1;
  • ECOG performance score 0 or 1;
  • Life expectancy ≥ 3 months;
  • Patients who have sufficient Baseline organ function and whose laboratory data meet the following criteria at enrollment:
Show all 16Show fewer
  • Absolute neutrophil count （ANC）≥1.5 × 109/L;
  • Platelets ≥100 × 109/L;
  • Hemoglobin ≥90g/dL;
  • Liver function:
  • Serum bilirubin ≤1.5 × upper limit of normal (ULN) or ≤ 3×ULN in any subject with Gilbert's Syndrome; Aspartate aminotransferase（AST） and alanine aminotransferase（ALT） ≤2.5 × ULN without liver metastases, or ≤5 × ULN if the patient has documented liver metastases;
  • International normalization ratio ≤1.2 if the patient is not on anticoagulants, or ≤3 if the patient is on anticoagulants;
  • Serum creatinine ≤1.5 mg/dL, or estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2;
  • Women of childbearing potential must have a negative serum pregnancy test prior to study entry, and agree to use adequate contraception from study entry through at least 1 month after the last dose of study drug. A female patient of nonchildbearing potential will have had at least 12 continuous months of natural (spontaneous) amenorrhea, follicle stimulating hormone level ≥40 mIU/mL at Screening, and an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms), or have had surgical bilateral oophorectomy, hysterectomy, or tubal ligation ≥6 weeks prior to Screening; in the case of oophorectomy alone, reproductive status will be confirmed by hormone level assessment;
  • A male patient must agree to use adequate contraception (male condom with spermicide or provide evidence of successful vasectomy; sterile sexual partner; or female sexual partner who uses an intrauterine device with spermicide, a female condom with spermicide, a contraceptive sponge with spermicide, an intravaginal system, a double diaphragm with spermicide, a cervical cap with spermicide) from study entry through at least 1 month after the last dose of study drug;
  • Patients must provide written informed consent prior to any study procedures.

Who cannot join

  • Disease
  • Patients with symptomatic central nervous system (CNS) metastases or carcinomatous meningitis; Note: Patients with treated CNS metastases may participate in this trial if the patient has completed radiotherapy or surgery for CNS metastases >2 weeks prior to study entry and if the patient is neurologically stable ≥ 2 weeks (no new neurologic deficits from brain metastasis on Screening clinical examination, no new findings on CNS imaging, and no corticosteroids being used).
  • Medical Conditions
  • Patients who have a history of another primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix. A patient who has had no evidence of disease from another primary cancer for 3 or more years is allowed to participate in the study;
  • Patients who have a known history of active hepatitis C or chronic hepatitis B ("active hepatitis" defined as HCV RNA level ≥ 103 copies/mL for hepatitis C or HBV DNA level ≥ 104 copies/mL for hepatitis B at Screening);
  • Patients who have a known diagnosis of human immunodeficiency virus (HIV);
Show all 35Show fewer
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the Investigator and Sponsor, could affect the patient's participation in the study such as:
  • Uncontrolled diabetes mellitus, HbA1c≥8%;
  • Malignant illnesses that are uncontrolled or whose control may be jeopardized by treatment with this study treatment;
  • Moderate or severe hepatic impairment, i.e., Child-Pugh class B or C (see appendix 8.6);
  • Autoimmune disorders with systemic therapy;
  • Patients who with an allo-transplant of any kind (including those with a xenograft heart valve);
  • Any significant ophthalmologic abnormality, including but not limited to the following:
  • Grade 2 or greater severity syndrome of dry eye;
  • Keratoconjunctivitis sicca;
  • Sjogren's syndrome;
  • Iritis;
  • Patients who have a history of definite neurological disorders that affected brain function activity, including epilepsy or dementia;
  • Active infections requiring antibiotic intravenous therapy at Screening;
  • Pregnancy or lactation;
  • Patients with any comorbid medical disorder that, in the opinion of the Investigator or Sponsor, may increase the risk of toxicity; Organ Function and Laboratory Values
  • Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:
  • Baseline QT interval corrected for heart rate using Fridericia's formula >480 msec or congenital long QT syndrome;
  • Concomitant diseases that could prolong the QT interval, as assessed by the Investigator, such as autonomic neuropathy (caused by diabetes or Parkinson's disease), cirrhosis, uncontrolled hypothyroidism, or grade 3 or greater severity electrolyte abnormality (CTCAE v5.0);
  • Concomitant medications known to prolong the QT interval;
  • History or presence of serious uncontrolled ventricular arrhythmias;
  • Left ventricular ejection fraction <50% assessed by echocardiogram;
  • Any of the following within 3 months prior to the first dose of study medication: myocardial infarction, severe/unstable angina, coronary artery bypass graft, congestive heart failure, cerebrovascular accident, or transient ischemic attack;
  • Other clinically significant heart disease such as congestive heart failure NYHA Class Ⅱ or greater severity and requiring heart transplant or uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg, in spite of antihypertensive medication); Prior Therapy
  • Chemotherapy, biologic therapy, herbal therapy, radiotherapy or investigational agents within 5 half lives or within 4 weeks (whichever is longer) prior to administration of the first dose of study drug on Day 1 or have not recovered to grade 1 or below from the side effects of such therapy (excluding cases of alopecia);
  • Patients received potent CYP3A4 inducer or inhibitor within 2 weeks prior to administration of the first dose of study drug on Day 1.
  • Patients received systemic corticosteroids within 2 weeks prior to administration of the first dose of study drug on Day 1.
  • Major surgery for any cause within 4 weeks of first dosing;
  • Treated with immunomodulator (e.g., motolimod, GS9688, IMO4200, E-6742, E-6887, etc).
  • Patients who have a history of allergic reactions (significant urticaria, angioedema, anaphylaxis) attributed to compounds of similar chemical or biologic composition to DN1508052-01; Patients with scheduled surgeries or who are, in the Investigator's opinion, likely to require surgery.

Trial locations and contacts

3 sites in 1 country.

United States3 sites

  • University of California San Diego-Moores Cancer Center

    La Jolla, California, 92093

  • University of Washington - Seattle Cancer Care Alliance

    Seattle, Washington, 98109

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri, 20237

Other trials in United States

About this study

Official title: A Phase Ⅰ, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of DN1508052-01 as a Single Agent When Administered Subcutaneously to Adult Patients With Advanced Solid Tumors

This is a phase I, open-label, multicenter study in adult patients with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists. DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 in 28-day cycles. Other dose regimens may be explored based on the analysis of emerging PK, pharmacodynamics (PD) and safety data. This study is designed to determine the MTD, RP2D and investigate the safety, tolerability, PK, biomarkers, HPV status and ISR in DN1508052-01-treated patients.

Read the detailed description

Study Population is adult patients (≥18 years) with histologically or cytologically confirmed, unresectable advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists.The selected starting dose, 0.01 mg/m2 of DN1508052-01, SC, on Day 1, Day 8 and Day 15 of each cycle.The starting dose will proceed with one patient. The next dose 0.1 mg/m2 will be explored if safety data permit in that there is no instance of a ≥ Common Terminology Criteria for Adverse Event (CTCAE v5.0) Grade 2 AE that is at least possibly related to the study intervention.then Dose escalation will then proceed following the 3+3 cohorts design.Dose escalation will continue until MTD or RP2D is reached, or the dose escalation will be terminated at the discretion of Investigators and Sponsor (or its designee) based on the analyses of emerging PK, PD, safety and efficacy data.The Primary objective is to determine the maximum tolerated dose (MTD) and recommended phase Ⅱ dose (RP2D) and assess dose-limiting toxicity (DLT) of DN1508052-01 as a single agent when administered subcutaneously to adult patients with advanced solid tumors.

Being tested
DN1508052-01

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DN1508052-01Drug

    DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the maximum tolerated dose (MTD)

    MTD is the highest dose of DN1508052-01 in subjects with DLT less than 33.3% during the DLT observation in the dose escalation

    Measured: 28 days

Secondary outcomes (7)

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Assessment of the cidence and severity of treatment-related AEs in who received at least 1 dose of in DN1508052-01

    Measured: Up to 24 months

  2. Time to peak (Tmax) of plasma concentration

    Pharmacokinetics profile of DN1508052-01 :Time to peak (Tmax) of plasma concentration

    Measured: Up to 2 months

  3. Maximum plasma concentration (Cmax)

    Pharmacokinetics profile of DN1508052-01 : Maximum plasma concentration (Cmax)

    Measured: Up to 2 months

  4. Halflife (T1/2)

    Pharmacokinetics profile of DN1508052-01 : Halflife (T1/2)

    Measured: Up to 2 months

  5. Clearance/ bioavailability (CL/F)

    Pharmacokinetics profile of DN1508052-01 : Clearance/ bioavailability (CL/F)

    Measured: Up to 2 months

  6. Area under curve (AUC)

    Pharmacokinetics profile of DN1508052-01 : Area under curve (AUC)

    Measured: Up to 2 months

  7. Efficacy Assessments

    Subjects will be assessed using RECIST v1.1. The primary aim is to demonstrate clinically meaning in ORR

    Measured: Up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2019
  2. Study start18 Sep 2019
  3. Primary completion30 Aug 2022
  4. Study completion30 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
A phase Ⅰ,multi-center, open-label
Masking
None (open label)
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03934359
Sponsor's protocol ID
DN1508052-01-101
Status last verified
Nov 2022
First submitted
28 Apr 2019
Last updated
18 Nov 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing DN1508052-01 in people with Advanced Solid Tumors, run by Shanghai De Novo Pharmatech Co., Ltd. at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the maximum tolerated dose (MTD) (time frame: 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03934359.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in